Cardiac Intelligence drives our pipeline, anchored by three late-stage programs.
Fueled by deep scientific expertise and a passion for helping people with cardiovascular diseases, Kardigan has curated a diverse pipeline of early and late-stage clinical programs, each designed to move beyond symptom management and to redefine treatment approaches where patients and their families need it most. Every program we invest in adds to our Cardiac Intelligence and fuels our growth.
1 Kardigan in-licensed exclusive worldwide development and commercialization rights to danicamtiv, an investigational drug discovered at MyoKardia and further developed by Bristol Myers Squibb.
2 Kardigan acquired rights to ataciguat, an investigational drug developed by, and in-licensed from, Sanofi and Mayo Clinic.
3 Kardigan in-licensed exclusive worldwide development and commercialization rights to tonlamarsen, an investigational drug discovered and developed by Ionis.
4 Kardigan in-licensed exclusive worldwide development and commercialization rights to KAR-141, an investigational drug developed by Bristol Myers Squibb.